NCT06402851 - Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE) | Biotech Hunter

Enrollment

1,500

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Atrium; FibrillationChronic Kidney Diseases

Interventions

DRUG

Anticoagulant Oral

Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.

Trial Locations (6)

ACTIVE_NOT_RECRUITING

Hospital Ana Nery, Salvador

ACTIVE_NOT_RECRUITING

Instituto de Cardiologia do DF, Brasília

ACTIVE_NOT_RECRUITING

Hospital Universitário Maria Aparecida Pedrossian - EBSERH, Campo Grande

ACTIVE_NOT_RECRUITING

Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo

RECRUITING

Hospital Universitário São Francisco na Providência de Deus, Bragança Paulista

RECRUITING

Santa Casa de Misericórdia de Ponta Grossa, Ponta Grossa